Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
- PMID: 34911744
- DOI: 10.1136/gutjnl-2021-326312
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Keywords: IBD; immune response; infectious disease.
Conflict of interest statement
Competing interests: JS has received lecture fees from Takeda and from the Falk Foundation.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous